Monopar Therapeutics Inc. (MNPR)

$2.57

+0.07 (+2.80%)
Rating:
Recommendation:
-
Symbol MNPR
Price $2.57
Beta 0.905
Volume Avg. 0.03M
Market Cap 33.039M
Shares () -
52 Week Range 1.391-4.88
1y Target Est -
DCF Unlevered MNPR DCF ->
DCF Levered MNPR LDCF ->
ROE -57858039.10% Strong Sell
ROA -63019686.31% Strong Sell
Operating Margin -
Debt / Equity 15.47% Neutral
P/E -3.34 Strong Sell
P/B 2.62 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MNPR news


Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc
Healthcare
Biotechnology
NASDAQ Capital Market

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.